INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (9,838)	$ (12,156)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,031	$ 1,002
Gain from sale of property and equipment, net	(1)
Accretion of discount, amortization of premium and changes in accrued interest of marketable securities	146	$ 145
Gain from sale of investments of available-for-sale marketable securities	(20)	(197)
Stock-based compensation to employees, directors and non-employees consultants	1,571	1,754
Decrease in Office of the Chief Scientist receivables	1,541	2,105
Decrease (increase) in other accounts receivable	1,032	(184)
Decrease in trade payables	(953)	(772)
Increase (decrease) in other accounts payable, accrued expenses and other long-term liabilities	1,051	(417)
Decrease in deferred revenues	(2,847)	(190)
Decrease in advance payment from United Therapeutics	(93)	(104)
Increase in interest receivable on short-term deposits	(39)	(14)
Linkage differences and interest on short and long-term deposits	24	65
Accrued severance pay, net	6	(63)
Net cash used by operating activities	(7,389)	(9,026)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(1,471)	(552)
Repayment of (investment in) short-term deposits	(8,794)	11,072
Repayment of long-term deposits	5	3
Proceeds from sale of property and equipment	3
Proceeds from sale of available-for-sale marketable securities	1,054	2,409
Proceeds from redemption of available-for-sale marketable securities	651	301
Investment in available-for-sale marketable securities	(2,543)	(2,513)
Net cash provided (used) by investing activities	(11,095)	10,720
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds related to issuance of common stock in a private placement	790	528
Exercise of options and warrants	16	246
Net cash provided by financing activities	806	774
Increase (decrease) in cash and cash equivalents	(17,678)	2,468
Cash and cash equivalents at the beginning of the period	22,626	4,493
Cash and cash equivalents at the end of the period	4,948	6,961
Supplemental disclosure of cash flow activities:
Taxes paid due to non-deductible expenses	43	17
Supplemental disclosure of non-cash activities:
Purchase of property and equipment on credit	132	$ 72
Share consideration to contractor	$ 39